VisEn unveils Cat-K fluorescence molecular imaging agent

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

VisEn Medical, a developer of fluorescence in vivo imaging, has launched its new Cat-K Fluorescent Activatable Sensor Technology (FAST) imaging agent for measuring and monitoring Cathepsin K activity associated with disease progression and therapeutic response.

Cathepsin K expression is a biomarker and therapeutic target for a range of bone-related diseases, including cancer metastasis to bone, as well as atherosclerosis. The Cat-K FAST agent will seek to expand research and enhance drug development in these areas by enabling real-time imaging of Cat-K activity, according to the Bedford, Mass.-based company.